Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 4/20 | 0.33 |
| ▸ | DRD4 | P21917 | 4/20 | 0.33 |
| ▸ | HTR1B | P28222 | 4/20 | 0.33 |
| ▸ | DRD3 | P35462 | 3/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | DUT | P33316 | 2/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20605123 | 1.00 | DRD2 (0.35) | DRD2HTR2AHTR1ADRD4HTR1B | |
| SCHEMBL23799358 | 0.88 | MCL1 (0.33) | MCL1 | |
| SCHEMBL23800535 | 0.88 | MCL1 (0.33) | MCL1 | |
| SCHEMBL20604886 | 0.85 | DRD2 (0.38) | DRD2HTR2AHTR1ADRD4HTR1B | |
| SCHEMBL20604926 | 0.80 | DRD2 (0.39) | DRD2HTR2AHTR1ADRD4HTR1B | |
| SCHEMBL20604874 | 0.80 | DRD2 (0.41) | DRD2HTR2AHTR1ADRD4HTR1B | |
| SCHEMBL20605112 | 0.80 | DUT (0.37) | AOC3DUTMCL1 | |
| SCHEMBL20604875 | 0.79 | DRD2 (0.36) | DRD2HTR2AHTR1ADRD4HTR1B | |
| SCHEMBL20604923 | 0.77 | HTR1A (0.44) | DRD2HTR2AHTR1ADRD4HTR1B | |
| SCHEMBL20604925 | 0.77 | HTR1A (0.42) | DRD2HTR2AHTR1ADRD4HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | DRD2 3801/4885HTR2A 1729/4885HTR1A 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.